Introduction: According to global statistics, stroke is known as the main health problem in the world. Many clinical and molecular research, which are stored in the different repository with the various format have been conducted in the area of stroke domain. The heterogeneity of these research data does not make a comprehensive view of the disease. Recently, translational research has been developed to fill the gap between these studies. In this study, we used the integrative disease modeling method to model the underlying mechanism of stroke risk factors.
Material and Methods: This study was conducted in three steps: data gathering, model construction, and mechanism discovery. First, using semantic and information retrieval tools, we extracted the cause and effect statement from the literature to create the mechanistic model, and the validated molecular data to evaluate the constructed model. Then, the integrative model was created and evaluated. Finally, we used Gene Set Enrichment Analysis to identify the main biological process and signaling pathways in the mechanism of the disease.
Results: In the evidence-based information retrieval from the literature, 1837 causal statement was extracted. The initial network was created with 648 nodes (molecular, clinical, and environmental factors) and 1837 edges (interactions). Also, 51 genes/proteins and nine single nucleotide polymorphisms were matched with data in the model. The inflammatory response, response to lipid, regulation of body fluid levels, and regulation of response to stress, complement and coagulation cascades, and PPAR signaling pathway were the main biological processes and signaling pathways enriched in GSEA analysis.
Conclusion: This study showed that we can identify the underlying mechanism of stroke risk factors and use a proper strategy to prevent it, using Integrative Disease Modeling.
Naghavi M, Alemu Abajobir A, Abbafati C, Abbas KM, Abd-Allah F, Ferede Abera S, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017/09/19. 2017; 390(10100):1151–210. PMID: 28919116 DOI: 10.1016/S0140-6736(17)32152-9
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009; 27(5): 493-501. PMID: 19342825 DOI: 10.1159/000210432
Buczek J, Czlonkowska A. Stroke and genetics. Periodicum Biologorum. 2012; 114(3): 259–66.
Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery the pharmaceutical industry perspective. Stroke. 2009; 40(3 suppl 1): S121–5. PMID: 19064772 DOI: 10.1161/STROKEAHA.108.535104
Caffes N, Kurland DB, Gerzanich V, Simard JM. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci. 2015; 16(3): 4973–84. PMID: 25749474 DOI: 10.3390/ijms16034973
Audebert HJ, Sobesky J. Stroke: ’Time is brain’ after stroke, regardless of age and severity. Nat Rev Neurol. 2014; 10(12): 675–6. PMID: 25330727 DOI: 10.1038/nrneurol.2014.194
Woolf SH. The meaning of translational research and why it matters. JAMA. 2008; 299(2): 211-3. PMID: 18182604 DOI: 10.1001/jama.2007.26
Habibi-Koolaee M, Shahmoradi L, Niakan Kalhori SR, Ghannadan H, Younesi E. Prevalence of stroke risk factors and their distribution based on stroke subtypes in Gorgan: A retrospective hospital-based study - 2015-2016. Neurol Res Int. 2018; 2018: 2709654. PMID: 30147952 DOI: 10.1155/2018/2709654
Habibi-Koolaee M, Shahmoradi L, Niakan Kalhori SR, Ghannadan H, Hosseini A, Younesi E. Lipid profile and the risk of stroke: A study from North of Iran. Journal of Research in Medical and Dental Science. 2018; 6(1): 343–9.
Berthold MR, Cebron N, Dill F, Gabriel TR, Kötter T, Meinl T, et al. KNIME: The Konstanz information miner. In: Preisach C, Burkhardt H, Schmidt-Thieme L, Decker R (eds). Data analysis, machine learning and applications. Studies in Classification, Data Analysis, and Knowledge Organization. Springer; 2007.
Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 2011; 27(3): 431–2. PMID: 21149340 DOI: 10.1093/bioinformatics/btq675
Micha R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: A fresh look at the evidence. Lipids. 2010; 45(10): 893-905. PMID: 20354806 DOI: 10.1007/s11745-010-3393-4
DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011; 108(3 Suppl): 3B-24B. PMID: 21802577 DOI: 10.1016/j.amjcard.2011.03.013
Sowers JR. Diabetes in the elderly and in women: cardiovascular risks. Cardiol Clin. 2004; 22(4): 541-51. PMID: 15501622 DOI: 10.1016/j.ccl.2004.06.008
Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: Systematic review and meta-analysis. Cerebrovasc Dis. 2014; 37(1): 64-75. PMID: 24401164 DOI: 10.1159/000356789
Demarin V, Lisak M, Morovic S, Cengic T. Low high-density lipoprotein cholesterol as the possible risk factor for stroke. Acta Clin Croat. 2010; 49(4): 429–39. PMID: 21830454
Tkac T. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease. Acta Diabetol. 2003; 40 (Suppl 2): S338-42. PMID: 14704865 DOI: 10.1007/s00592-003-0116-9
Yamaoka-Tojo M, Tojo T, Takahira N, Masuda T, Izumi T. Ezetimibe and reactive oxygen species. Curr Vasc Pharmacol. 2011; 9(1): 109–20. PMID: 21044015 DOI: 10.2174/157016111793744652
Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. International Journal of Clinical Practice. 2006; 60(1): 48–56.
Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep. 2008; 10(1): 11–8. PMID: 18366980 DOI: 10.1007/s11883-008-0003-5
Mehta SL, Li PA. Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke. J Cereb Blood Flow Metab. 2009; 29(6): 1069–78. PMID: 19240738 DOI: 10.1038/jcbfm.2009.4
Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-gamma: Therapeutic target for ischemic stroke. Trends Pharmacol Sci. 2007; 28(5): 244–9. PMID: 17416424 DOI: 10.1016/j.tips.2007.03.004
Walcher D, Marx N. Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol. 2009; 31(1): 103–11. PMID: 19347338 DOI: 10.1007/s00281-009-0144-9